Kevin Eggan

Pain in a dish

November 24, 2014

Turning skin cells into pain-sensing neurons


Human noxious stimulus detecting sensory neurons produced by converting skin cells with a set of five genes to this new fate—enabling study of "pain"in a dish. (Credit: Elizabeth Buttermore, PhD)

Patient stem cells help identify common problem in ALS

April 3, 2014

Discovery will lead directly to clinical trials

Harvard stem cell scientists have discovered that a recently approved medication for epilepsy may possibly be a meaningful treatment for amyotrophic lateral sclerosis (ALS)—Lou Gehrig’s disease, a uniformly fatal neurodegenerative disorder. The researchers are now collaborating with Massachusetts General Hospital to design an initial clinical trial testing the safety of the treatment in ALS patients.

Kevin Eggan named a member of a new Stem Cell Research Consortium

March 26, 2013

HSCI's Kevin Eggan has been named a member of a new Stem Cell Research Consortium established by the Cure Alzheimer's Fund. The six consortium scientists, at academic research institutions in the US and Israel will be using techniques pioneered by Eggan, an HSCI Principal Faculty member and a professor in Harvard's Department of Stem Cell and Regenerative Biology, to study in the laboratory the neurons created from the cells of patients at high genetic risk of developing Alzheimer's.

Stem cell lessons: Insights on SCNT in studies, commentary

October 5, 2011

Five years after Harvard researchers first received institutional permission to attempt to produce stem cell lines via somatic cell nuclear transfer (SCNT), a young scientist who worked in the Harvard program as a postdoctoral fellow has succeeded in using the process — known as therapeutic cloning — to produce a stem cell line containing the genes of a patient with type 1 diabetes.

From skin cells to motor neurons: researchers find success with direct cellular reprogramming

August 29, 2011

A team of Harvard stem cell researchers has succeeded in reprogramming adult mouse skin cells directly into the type of motor neurons damaged in amyotrophic lateral sclerosis (ALS), best known as Lou Gehrig’s disease, and spinal muscular atrophy (SMA). These new cells, which researchers are calling induced motor neurons (iMNs), can be used to study the development of the paralyzing diseases and to develop treatments for them.